More than 30 m people across the US are living with diabetes, and foot problems including foot ulcers are common complications that, without proper treatment, can lead to hospital admissions and even amputations.
The ADA Compendium was compiled by a panel of contributing authors and distributed this month to health care professionals who subscribe to the ADA's peer-reviewed journals Diabetes Care and Diabetes. Healogics is passionate about providing wound carefor the 25% of diabetics who will experience a foot ulcer at some point in their life.
The Compendium has been distributed to Healogics' 4,000 affiliated physicians and will be distributed to thousands more who entrust their patients care to Healogics Wound Care Centers across the country.
An estimated 15% of those with a diabetic foot ulcer will experience an amputation.
Over the past year, Healogics has sought to advance the science, awareness and practice of wound care through the Wound Science Initiative.
The Wound Science Initiative includes collaborations such as this one with advocacy organizations including the ADA and other academic and scientific leaders. Healogics seeks to unite and educate key stakeholders across the healthcare environment to ensure that chronic wound patients receive the highest quality evidence-based care.
These aims will be achieved by leveraging Healogics vast clinical database of over three m records to advance the science and practice of wound care through research, technology and collaboration.
Patients with an amputation have a 50% mortality rate within five years.
Healogics' support of the ADA includes advertising in print and digital publications, including Diabetes Care, Clinical Diabetes and Diabetes Forecast and events at future scientific symposiums.
Headquartered in Jacksonville, Fla., Healogics is the nation's wound healing expert. Last year over 330,000 patients received advanced wound care through a nationwide network of nearly 700 Wound Care Centers.
The Healogics team is made up of almost 3,000 employees, 4,000 affiliated physicians and a Healogics Specialty Physician practice group of nearly 300. In addition to the company's network of outpatient Centers, Healogics partners with over 300 skilled nursing facilities to care for patients with chronic wounds, and provides inpatient consults at more than 80 partner hospitals.
Ascletis Pharma Inc doses first participant in global Phase III clinical programme of ASC30
Daiichi Sankyo data highlight real-world impact of bempedoic acid on cardiovascular risk
Nippon Kinzoku begins mass production of ultra-thin stainless steel for insulin needles
Hanmi Pharm enters exclusive licensing deal with Genentech for obesity therapy HM17321
Annexin Pharmaceuticals receives proposed INN vanexin for ANXV
Aqua Medical treats second type 2 diabetes patient in IDE trial of investigational PIMA procedure
ImmuPharma selects Kymos Group as bioanalytical partner for Kapiglucagon
Biocon launches Yesafili biosimilar in US ophthalmology market
Stevanato Group expands European adoption of Alina pen injector platform
Ascletis to discuss ASC36_35 FDC preclinical weight loss data at EASD annual meeting
Arch Biopartners engages private lab to advance IL-32 chronic kidney disease programme
Insulet expands European footprint with Omnipod 5 and Omnipod Discover launch in Spain